I am happy to share the publication of the #first paper from my #dissertation research, exploring the impact of deprescribing interventions in #community-based healthcare settings
Established thrombotic risk factors commonly present in semaglutide users include: Obesity (BMI 30 kg/m), which increases VTE risk 2-3 fold [13] Type 2 diabetes and insulin resistance Prolonged immobility or sedentary lifestyle History of previous blood clots Active cancer or recent cancer treatment Recent surgery, particularly orthopedic or abdominal procedures Smoking Certain medications, including estrogen-containing contraceptives or hormone replacement therapy Inherited thrombophilias (clotting disorders) Advanced age (risk increases after age 60) Pregnancy and postpartum period (note that semaglutide should be discontinued when pregnancy is recognized) Patients initiating semaglutide should undergo comprehensive baseline assessment including medical history review, with particular attention to prior thrombotic events and family history of clotting disorders
Semaglutide belongs to a class of medications called GLP-1 receptor agonists, which mimic a natural hormone that controls hunger and blood sugar
Ann Neurol 72:156166 Wofford KL, Loane DJ, Cullen DK (2019) Acute drivers of neuroinflammation in traumatic brain injury
With months of research into the product conducted by the team we are begun refulary offering these aesthetics courses every month within our academies
